CRO in Nigeria: A Guide for Pharmaceutical Companies

Introduction

Developing a new medicine, vaccine, or medical device requires more than scientific innovation. It involves careful planning, regulatory compliance, clinical trial management, participant safety, data collection, and collaboration among multiple stakeholders.

For pharmaceutical companies, biotechnology firms, medical device manufacturers, and research institutions looking to conduct clinical research in Nigeria, managing these activities can be complex. This is where a Contract Research Organisation (CRO) becomes an important partner.

A CRO provides specialised research services that help sponsors plan, manage, and conduct clinical trials and other research activities. By working with a qualified CRO in Nigeria, sponsors can access local research expertise, operational support, and knowledge of the country’s clinical research environment.

As Nigeria continues to develop its clinical research capacity, understanding the role of CROs is increasingly important for organisations seeking to evaluate new treatments, generate reliable clinical evidence, and expand their research programmes into the Nigerian market.

In this guide, we explain what a CRO does, the services it provides, when pharmaceutical companies need one, what Nigerian regulators expect, and what to consider when selecting a clinical research partner in Nigeria.

What Is a Contract Research Organisation (CRO)?

A Contract Research Organisation is an organisation contracted by a pharmaceutical company, biotechnology firm, medical device manufacturer, academic institution, or other research sponsor to perform specific research-related duties. International Good Clinical Practice (GCP) standards describe a CRO in similar terms: a person or organisation contracted by the sponsor to carry out one or more of the sponsor’s trial-related duties and functions.

These services may include clinical trial management, data management, regulatory affairs, biostatistics, and other activities required to implement a clinical study.

In Nigeria, the National Agency for Food and Drug Administration and Control (NAFDAC) has also published eligibility criteria that a CRO must meet in order to conduct clinical trials in the country. We cover these in the regulatory section below.

Rather than building every research function internally, a sponsor can engage a CRO to provide the expertise, personnel, and operational support needed for some or all of its clinical development activities. Depending on the agreement, a CRO may support a single component of a study or coordinate multiple stages of the clinical trial process.

For example, a pharmaceutical company developing a new treatment may engage a CRO to identify suitable clinical trial sites, support regulatory submissions, coordinate investigators, monitor study conduct, manage clinical data, and prepare study reports.

The scope of work depends on the sponsor’s requirements, the study design, the CRO’s capabilities, and the responsibilities formally assigned under the contract.

What Does a CRO Do?

A CRO helps translate a clinical development plan into an organised research programme. Its responsibilities may extend from early study planning to trial completion and reporting.

1. Clinical trial planning and management

Before a clinical trial begins, sponsors need a clear operational plan covering study objectives, timelines, resources, participating sites, and responsibilities.

A CRO can support study planning, feasibility assessments, project management, site coordination, budgeting, and the development of operational timelines.

Effective planning helps sponsors identify potential challenges early and coordinate the different activities required to conduct a study.

2. Regulatory affairs and ethics support

Clinical trials must comply with applicable regulatory requirements and ethical standards.

In Nigeria, NAFDAC’s guidelines state that no clinical trial may begin unless the Agency has given written authorisation. Independent ethics review is also required, and NAFDAC asks applicants to show that the reviewing ethics committee is accredited by the National Health Research Ethics Committee (NHREC).

A CRO may help sponsors prepare regulatory documentation, coordinate submissions, respond to regulatory queries, and work with investigators and ethics committees.

However, engaging a CRO does not remove the need for the appropriate regulatory authorisations and ethical approvals. Responsibilities and submission requirements should be confirmed for each study.

3. Clinical trial site identification and management

Clinical research depends on suitable investigators, healthcare facilities, trained personnel, and adequate infrastructure.

A CRO may evaluate potential research sites, assess their feasibility, coordinate site activation, and support communication between investigators and sponsors.

Site selection can involve reviewing patient populations, investigator experience, staff capacity, facilities, equipment, recordkeeping, and the site’s ability to follow the study protocol.

For international sponsors entering Nigeria, a partner with knowledge of the local research environment can help identify operational requirements that need to be addressed before a study begins.

4. Patient recruitment and retention

Recruiting eligible participants is one of the important operational challenges in clinical research.

CROs may work with investigators and research sites to develop recruitment plans, identify appropriate recruitment channels, and improve participant engagement.

Retention strategies can include clear communication, appropriate follow-up, convenient study visits, and respectful engagement with participants.

All recruitment and retention activities must follow the approved protocol, eligibility criteria, informed consent requirements, and applicable ethical standards.

5. Clinical monitoring and quality assurance

Clinical monitoring helps assess whether a trial is being conducted according to its protocol, applicable requirements, and Good Clinical Practice (GCP).

Depending on the contracted services, a CRO may conduct monitoring visits, review study documentation, identify deviations, follow up on outstanding issues, and support corrective and preventive actions.

Quality assurance activities may also include audits and reviews of systems and processes.

These activities help protect participants and support the reliability and integrity of clinical trial data.

6. Clinical data management and biostatistics

Clinical trials generate data that must be collected, reviewed, managed, and analysed appropriately.

CRO services may include clinical data management, electronic data capture support, statistical analysis planning, biostatistics, and preparation of clinical study reports.

Accurate data handling and appropriate statistical methods are essential for interpreting study findings and determining what conclusions the evidence can support.

7. Laboratory and bioanalytical support

Some clinical studies require specialised laboratory services to analyse biological samples, measure biomarkers, evaluate immunogenicity, or assess the pharmacokinetics of an investigational product.

Depending on the study, these services may be delivered by a CRO’s own laboratory facilities or through qualified laboratory partners.

Sponsors should evaluate laboratory methods, sample handling procedures, equipment, quality systems, and relevant technical capabilities when selecting a research partner.

8. Safety reporting and pharmacovigilance

Clinical trials require systems for identifying, documenting, assessing, and reporting safety information.

Depending on the contracted scope, a CRO may support adverse event processing, safety documentation, reporting coordination, and pharmacovigilance activities.

NAFDAC’s 2024 clinical trial application guidelines require that the Agency be notified of any Serious Adverse Events within seven calendar days of receiving the information. The specific responsibilities of the sponsor, CRO, investigators, and other service providers should therefore be documented clearly, so that safety information is handled within the required timelines.

When Should a Pharmaceutical Company Engage a CRO in Nigeria?

A pharmaceutical company does not necessarily need to outsource every aspect of its research programme. However, engaging a CRO can be valuable when a sponsor requires specialised expertise or local operational support.

Consider engaging a CRO when:

You are entering the Nigerian market. Your organisation needs local knowledge of clinical research operations, applicable regulatory requirements, and research site capabilities.
You lack an in-house clinical operations team. A CRO can provide access to appropriately qualified professionals and established research processes.
You are planning a complex clinical trial. Studies involving multiple sites, specialised assessments, or large participant populations may require substantial coordination.
You need to establish clinical trial sites. A CRO can support feasibility assessments, site identification, qualification, and activation.
You need specialised technical services. These may include clinical data management, biostatistics, laboratory analysis, or pharmacovigilance.
You want to expand into multiple African countries. A CRO with relevant regional capabilities may help coordinate country-specific activities and local partners.

The decision should be based on the sponsor’s internal capabilities, study requirements, budget, timeline, and the level of responsibility it intends to outsource.

Why Is Nigeria Relevant to Clinical Research?

Nigeria is an important setting for clinical research because of its large population, varied healthcare needs, and opportunities to investigate diseases relevant to the country and the wider African region.

For sponsors, conducting research in Nigeria may help generate evidence in populations and healthcare settings relevant to the intended use of a treatment.

Potential areas of research include infectious diseases, sickle cell disease, cardiovascular conditions, diabetes, kidney disease, and other health priorities. The suitability of Nigeria for a particular study depends on its scientific objectives, target population, feasibility, available infrastructure, and regulatory requirements.

However, population size alone does not guarantee successful recruitment or trial delivery. Sponsors must assess the availability of eligible participants, investigator capacity, site readiness, healthcare infrastructure, logistics, and the practical requirements of the proposed protocol.

A capable local research partner can help sponsors evaluate these factors before committing resources to a study.

What Are the Regulatory Requirements for CROs and Clinical Trials in Nigeria?

Understanding the regulatory environment is an essential part of planning clinical research in Nigeria. NAFDAC publishes guidance on clinical trial applications, Good Clinical Practice, and eligibility criteria for CROs. The points below summarise that guidance; always confirm against the current official documents before starting a study.

Clinical trial authorisation

NAFDAC’s Guidelines for Clinical Trial Application in Nigeria, 2024 (effective 19 November 2024) set out the following:

Written authorisation is required. No person may commence or conduct a clinical trial unless NAFDAC has given written authorisation. No one may import, procure, or manufacture a drug product, cosmetic, or medical device for a clinical test without a valid Clinical Trial Approval.
Applications are made through NAFDAC’s electronic Clinical Trial Application Platform (eCTAP).
The application package is extensive. It includes the study protocol, informed consent form, patient information leaflet, Investigator’s Brochure, the sponsor-investigator agreement, evidence of NHREC accreditation of the ethics committee, ethics committee approval from participating centres, evidence of investigators’ basic GCP training within the last two years, investigator CVs, sample case report forms, evidence of insurance cover for participants, the name and qualification of the trial monitor, the Data Safety Monitoring Board list and charter, and conflict-of-interest declarations.
A pre-submission consultation meeting is optional. It gives sponsors a chance to discuss the study plan with NAFDAC before applying.
Queries are time-bound. If NAFDAC issues a Compliance Directive, the applicant is expected to respond within 15 working days.
Conduct and reporting obligations continue after approval. The study must follow the approved protocol, and protocol amendments need NAFDAC approval. NAFDAC may inspect approved trial sites, must be notified of Serious Adverse Events within seven calendar days, and expects progress reports during the trial and a final report at its end.

The guidelines also state that clinical trials are mandatory for certain products, such as new chemical entities, new indications, new combinations, and medical devices to be tested on humans, and that they apply to bioavailability and bioequivalence studies for generic medicines.

Research ethics review

The study must undergo independent ethics review, with approval obtained before the trial begins. NAFDAC requires evidence that the ethics committee is accredited by the National Health Research Ethics Committee (NHREC), together with ethics approval from each participating centre. Ethics approval does not replace NAFDAC authorisation, and NAFDAC authorisation does not replace ethics approval. Both are required.

Good Clinical Practice

Trials must follow NAFDAC’s Good Clinical Practice Guidelines, 2025, effective 5 May 2025. These are adapted from the international ICH E6(R3) GCP guideline, with adjustments for local conditions. They cover participant protection, informed consent, ethics committee review, quality management, monitoring, safety reporting, data integrity, and the roles of sponsors, investigators, and service providers.

Eligibility criteria for CROs

NAFDAC’s CRO eligibility criteria, published in June 2025, apply to CROs seeking approval to conduct Phase I, II, or III clinical trials in Nigeria. They include:

Registration with the Corporate Affairs Commission (or a recognised government entity).
Top management with relevant qualifications in pharmaceutical or medical sciences, or substantial clinical trial experience; and team members with demonstrated knowledge of GCP and the ethical principles of health research.
Strong understanding of NAFDAC’s regulatory requirements, including managing regulatory submissions and ensuring GCP compliance.
Experience across therapeutic areas such as small molecules, biologicals, vaccines, or medical devices.
End-to-end capability, from clinical operations and site selection to data collection and monitoring.
Technology capabilities, for example electronic data capture, remote monitoring tools, and participant engagement platforms.
Strategies and capacity to recruit and retain participants.
A track record of managing clinical trials.
A robust quality management system, and robust clinical, bioanalytical, and computerised systems, which are demonstrated during a pre-inspection for new applications or new facilities.
A biostatistician to ensure proper analysis of data.
A communication function that is responsive to sponsors and regulators.
A mandatory Annual Report of Compliance for continued operation as a CRO.

Regulatory requirements can change, and sponsors should consult current official guidance and obtain appropriate regulatory advice when planning a study.

How to Choose the Right CRO in Nigeria

Selecting a CRO is an important decision because the organisation may influence how efficiently a study is planned, conducted, monitored, and documented. Before entering into a contract, pharmaceutical companies should evaluate the following factors.

1. Compliance with NAFDAC’s CRO criteria

Ask the CRO how it meets NAFDAC’s published eligibility criteria, including its Corporate Affairs Commission registration, qualified management and staff, quality systems, biostatistics capability, and annual compliance reporting. Ask for evidence of its regulatory standing for the type and phase of study you plan.

2. Regulatory knowledge

Assess the CRO’s understanding of Nigerian regulatory requirements, clinical trial submissions through eCTAP, ethics review processes, and GCP. Ask how it manages regulatory documentation and communicates with relevant stakeholders.

3. Relevant experience

Evaluate the CRO’s experience in the therapeutic area, study phase, product type, and operational activities relevant to your project. Experience in one type of clinical trial does not automatically establish expertise in every other study type.

4. Clinical research site capabilities

Ask how the CRO identifies, evaluates, and coordinates research sites. Review the processes used to assess investigator qualifications, patient populations, facilities, and site readiness.

5. Quality management systems

Review the CRO’s standard operating procedures, training processes, documentation practices, deviation management, audit arrangements, and quality oversight.

6. Technical capabilities

Depending on your study, evaluate the CRO’s capacity in clinical monitoring, data management, biostatistics, laboratory services, safety reporting, and relevant technology systems.

7. Communication and project management

A CRO should be able to explain how it will report progress, manage risks, escalate issues, document decisions, and coordinate with the sponsor. Clear reporting arrangements are particularly important for international organisations managing studies across different locations.

8. Contractual responsibilities and accountability

The contract should clearly define the scope of work, deliverables, timelines, responsibilities, subcontracting arrangements, data access, quality expectations, and communication procedures.

Sponsors may transfer some or all trial-related duties to a CRO, but under NAFDAC’s GCP Guidelines the ultimate responsibility for protecting participants and for the reliability of trial data stays with the sponsor. The sponsor is also responsible for assessing a CRO’s suitability and for keeping appropriate oversight of the activities performed on its behalf, including any work the CRO subcontracts.

Why Work With Xcene Research?

Xcene Research is a Contract Research Organisation headquartered in Lagos, Nigeria, with a focus on clinical trials in Nigeria and Sub-Saharan Africa.

For pharmaceutical companies, biotechnology organisations, and other research sponsors exploring clinical development opportunities in the region, working with a research partner requires an understanding of both scientific objectives and local operational considerations. Xcene Research supports sponsors with the management and execution of clinical trials across phases, together with site management and laboratory-related support.

Every study is different. An initial conversation can help clarify your research objectives, the services you need, the technical capabilities required, and the feasibility of the proposed work in Nigeria and across the region.

Planning a clinical trial in Nigeria?

Connect with Xcene Research to discuss your clinical research objectives and explore potential opportunities for collaboration.

Contact Xcene Research to start a conversation about your research needs.

Frequently Asked Questions About CROs in Nigeria

What does CRO stand for in clinical research?

CRO stands for Contract Research Organisation. It is an organisation contracted by a research sponsor to perform specified clinical research or development activities.

What services does a CRO provide in Nigeria?

Depending on its capabilities and contractual scope, a CRO may provide clinical trial management, regulatory affairs support, site identification and management, clinical monitoring, data management, biostatistics, safety reporting, and laboratory-related services.

Does a CRO need NAFDAC approval to run clinical trials in Nigeria?

NAFDAC has published eligibility criteria that a CRO must meet to conduct Phase I, II, or III clinical trials in Nigeria. These cover areas such as corporate registration, qualified personnel, quality systems, biostatistics, and an annual report of compliance. Sponsors should ask any CRO they are considering how it meets these criteria.

How do I choose a CRO in Nigeria?

Evaluate the CRO’s compliance with NAFDAC’s criteria, regulatory knowledge, relevant experience, personnel, quality management systems, technical capabilities, research site network, communication processes, and ability to meet your study requirements.

A CRO may support or manage regulatory submissions when those duties are assigned to it. However, NAFDAC’s written authorisation and the required ethics approvals must still be in place before a trial begins. The responsibilities of the sponsor and CRO should be clearly documented.

Can an international pharmaceutical company conduct clinical trials in Nigeria?

International pharmaceutical companies may conduct clinical trials in Nigeria, provided the study meets the applicable regulatory, ethics, and other legal requirements. Sponsors should assess local feasibility and obtain the required authorisations before starting a trial.

What is the difference between a CRO and a clinical trial site?

A CRO is a service provider contracted to perform specified research-related duties for a sponsor. A clinical trial site is the location where study activities involving participants are conducted under the responsibility of the investigator and institution. A CRO may coordinate or monitor sites, but it does not replace the investigator’s responsibilities.

How much does it cost to hire a CRO in Nigeria?

CRO costs depend on the study phase, therapeutic area, number of sites, participant population, duration, complexity, laboratory requirements, and services outsourced. Sponsors should request a study-specific proposal based on a defined scope of work.

Conclusion

A Contract Research Organisation can be an important partner for pharmaceutical companies seeking to conduct clinical research in Nigeria. By providing specialised expertise and operational support, a CRO can help sponsors manage the many activities involved in clinical development.

Choosing the right partner requires careful evaluation of regulatory knowledge, compliance with NAFDAC’s CRO criteria, technical capabilities, quality systems, research site readiness, and project management processes.

For sponsors considering Nigeria or expanding clinical development into Africa, understanding the local research environment is an essential first step towards planning a well-designed, ethical, and scientifically robust clinical trial.

Xcene Research welcomes conversations with organisations exploring clinical research and development opportunities in Nigeria and across Africa. Contact our team to discuss your research objectives and potential collaboration.

References and further reading

Regulatory information in this article reflects NAFDAC guidance available as of October 2026. Requirements can change, so please confirm against the latest official documents before planning a study.

What Is a Contract Research Organisation (CRO)? A Guide for Pharmaceutical Companies in Nigeria